Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Andrew Chan on Aspirin's Link to Reduced Cancer Risk

May 4th 2015

Andrew T. Chan, MD, MPH, a research fellow in the Department of Nutrition at the Harvard School of Public Health, discusses the impact of aspirin of cancer risk.

Ramucirumab Approval Expanded, Breakthrough Designation for Crizotinib, and More

May 2nd 2015

FDA Approves Second-Line Ramucirumab for mCRC

April 24th 2015

The FDA has approved second-line ramucirumab in combination with FOLFIRI as a treatment for patients with metastatic colorectal cancer (mCRC) following progression an upfront bevacizumab-containing regimen.

Long-term Aspirin Use Decreases Risk of GI Cancers, Especially Colorectal

April 20th 2015

A recent study joins a body of evidence suggesting that long-term, regular aspirin use is associated with a reduced risk for cancer, with the most dramatic reduction being seen in colorectal cancer incidence.

Oral Fluoropyrimidine TAS-102 in Refractory mCRC

April 16th 2015

Use of Regorafenib in Refractory mCRC

April 16th 2015

Second-Line Therapy for RAS Wild-Type mCRC

April 16th 2015

Choosing Between VEGF and EGFR Targeted Therapy in mCRC

April 16th 2015

Newly Diagnosed mCRC Treatment Goals

April 16th 2015

Dr. James Fleshman on Minimally Invasive Surgery for Colorectal Cancer

April 8th 2015

James W. Fleshman Jr, MD, from the Department of Surgery and Internal Medicine at Baylor University Medical Center, discusses the surgical management of colorectal cancer.

Colorectal Cancer Management Requires Multidisciplinary Approach

April 7th 2015

In an interview with OncLive, James W. Fleshman Jr, MD, explained how technological advances and a growing commitment to a multidisciplinary approach have impacted the treatment of colorectal cancer.

FDA Label Update Emphasizes Importance of RAS Testing in mCRC

April 7th 2015

For further insight into the evolving role of expanded mutation analysis in mCRC, OncLive interviewed Marwan G. Fakih, MD, the director of Gastrointestinal Medical Oncology at City of Hope.

Controversies in Clinical Care: Questioning Research

March 23rd 2015

Maurie Markman, MD, offers examples of clinical trials where the interpretation of study results is worthy of considerable additional discussion or where justification for the actual conduct of the study can be called into question.

Tivozanib Improves PFS Versus Bevacizumab in NRP-1 Low mCRC

March 10th 2015

Low serum neuropilin-1 may indicate longer progression-free survival with tivozanib compared with bevacizumab as a first-line treatment for patients with metastatic colorectal cancer.

Dr. Cremolini on Identifying Molecular Markers in mCRC

February 25th 2015

Chiara Cremolini, MD, a medical oncologist at the Tuscan Tumor Institute in Pisa, Italy, discusses the necessary steps researchers must take to identify molecular markers in metastatic colorectal cancer (mCRC).

FDA Accepts NDA for TAS-102 in mCRC

February 24th 2015

The FDA has accepted an NDA for the oral nucleoside TAS-102 as a treatment for patients with refractory metastatic colorectal cancer.

Analysis Confirms Safety of Regorafenib in mCRC Among Best Responders

February 14th 2015

Adverse events among patients with metastatic colorectal cancer who responded best to regorafenib in the phase III CORRECT trial were "broadly similar" to the overall study population.

Final Thoughts on Improving Outcomes in CRC

January 30th 2015

Impact of Vitamin D on Colorectal Cancer Outcomes

January 30th 2015

Molecular Profiling in Colorectal Cancer

January 30th 2015